Fig. 5From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyPopulation correlations between amyloid PET using Centiloids and plasma A Aβ42/40 ratio and B p-tau181 based on standardized valueBack to article page